Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice

British Journal of Cancer

Volumn 73, Issue 4, 1996, Pages 522-524

  Webster, L K ^a   Cosson, E J ^a   Stokes, K H ^a   Millward, M J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Cremophor; Doxorubicin; Drug interaction; Pharmacokinetics

Indexed keywords

CREMOPHOR; DOXORUBICIN; DOXORUBICINOL; PACLITAXEL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; FEMALE; GLYCEROL; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; PACLITAXEL; SOLVENTS; TIME FACTORS;

EID: 0030041325     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.90     Document Type: Article

References (17)

1. BARTLETT NL, LUM BL, FISHER GA, BROPHY NA, EHSAN MN, HALSEY J AND SIKIC BI. (1994). Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J. Clin. Oncol., 12, 835-842.
2. BORST P, SCHINKEL AH, SMIT JJM, WAGENAAR E, VAN DEEMTER L, SMITH AJ, EIJDEMS EWHM, BAAS F AND ZAMAN GJR. (1993). Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol. Ther., 60, 289-299.
3. CHERVINSKY DS, BRECHER ML, BAKER RM, HOELCLE MJ AND TEBBI CK. (1993). Reversal of C1300 murine neuroblastoma multidrug resistance by Cremophor EL, a solvent for Cyclosporin A. Cancer Biother., 8, 67-75.
4. ELLIS AG, CRINIS NA AND WEBSTER LK. (1995). Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother. Pharmacol., (in press).
5. FRICHE E, JENSEN PB, SEHESTED M, DEMANT EJF AND NISSEN NN. (1990). The solvents Cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug-resistant Ehrlich ascites tumor. Cancer Commun., 2, 297-303.
6. GIANNI L, KEARNS C, GIANI A, CAPRI G, VIGANO L, LOCATELLI A, BONADONNA G AND EGORIN MJ. (1995). Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol., 13, 180-190.
7. GIBALDI M. (1991). Compartmental and noncompartmental pharmacokinetics. In Biopharmaceutics and Clinical Pharmacokinetics, 4th edn, pp. 14-23. Lea & Febiger: Philadelphia.
8. HOLMES FA, NEWMAN RA, MADDEN T, VALERO V, FRASCHINI G, WALTERS RS, BOOSER DJ, BUZDAR AU, WILEY J AND HORTOBAGYI UT. (1994). Schedule dependent pharmacokinetics in a phase I trial of Taxol and doxorubicin as initial chemotherapy for metastatic breast cancer. Ann. Oncol., 5 (suppl 2), 197.
9. KONGSHAUG M, CHENG LS, MOAN J AND RIMINGTON C. (1991). Interaction of Cremophor EL with human plasma. Int. J. Biochem., 23, 473-478.
10. LUM BL, KAUBISCH S, YAHANDA AM, ADLER KM, JEW L, EHSAN MN, BROPHY NA, HALSEY J, GOSLAND MP AND SIKIC BL. (1992). Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J. Clin. Ontol., 10, 1635-1642.
11. MAESSEN PA, MROSS KB, PINEDO HM AND VAN DER VIJGH WJH. (1987). Improved method for the determination of 4′-epidoxorubicin and seven metabolites in plasma by high-pressure liquid chromatography. J. Chrom., 417, 339-346.
12. SINICROPE FA, DUDEJA PK, BISSONNETTE BM, SAFA AR AND BRASITUS TA. (1992). Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J. Biol. Chem., 267, 24995-25002.
13. SONNICHSEN DS AND RELLING MV. (1994). Clinical pharmacokinetics of paclitaxel. Clin. Pharmacokinet., 27, 256-269.
14. SPEEG VK AND MALDONADO AL. (1994). Effect of the non-immunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo. Cancer Chemother. Pharmacol., 34, 133-136.
15. SYKES E, WOODBURN K, DECKER D AND KESSEL D. (1994). Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. Br. J. Cancer, 70, 401-404.
16. WEBSTER L, LINSENMEYER M, MILLWARD M, MORTON C, BISHOP J AND WOODCOCK D. (1993). Measurement of Cremophor EL following Taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype J. Natl Cancer Inst., 85, 1685-1690.
17. WOODCOCK DM, JEFFERSON S, LINSENMEYER ME, CROWTHER PJ, CHOJNOWSKI GM, WILLIAMS B AND BERTONCELLO I. (1990). Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res., 50, 4199-4203.